Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 02, 2015 11:30 AM ET


Company Overview of PhaseBio Pharmaceuticals, Inc.

Company Overview

PhaseBio Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs that focus on endocrine and metabolic disorders, and cardiovascular diseases. Its development candidates include PE0139, a novel super-long-acting basal insulin-ELP fusion for weekly dosing; and PB1046, a weekly VIP receptor agonist for treatment of acute and chronic heart failure and Duchenne muscular dystrophy-associated cardiomyopathy. PhaseBio Pharmaceuticals, Inc. was formerly known as Phase Bioscience, Inc. and changed its name to PhaseBio Pharmaceuticals, Inc. in November 2008. The company was founded in 2002 and is based in Malvern, Pennsylvania.

One Great Valley Parkway

Suite 30

Malvern, PA 19355

United States

Founded in 2002





Key Executives for PhaseBio Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 50
Executive Chairman
Co-Founder and Director
Chief Financial Officer
Age: 66
Senior Vice President of Clinical Development
Compensation as of Fiscal Year 2015.

PhaseBio Pharmaceuticals, Inc. Key Developments

PhaseBio Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 02:40 PM

PhaseBio Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 02:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.

PhaseBio Pharmaceuticals, Inc. Announces Management Appointments

PhaseBio Pharmaceuticals, Inc. announced the expansion of its leadership team. Clay Thorp, general partner at Hatteras Venture Partners, has been named Executive Chairman of the board of directors, Jonathan P. Mow has assumed the role of Chief Executive Officer, and James Ballance, Ph.D., has been appointed Vice President, Research and Scientific Affairs. Mr. Thorp is a general partner with Hatteras Venture Partners and brings many years of experience in starting and building biotechnology companies. Mr. Mow is a life sciences executive with more than 25 years of experience in biotech management. He previously served as Chief Business Officer of PhaseBio. Dr. Ballance has more than 25 years of experience in the biotech industry, within both small biotech and large pharma, specializing in early stage research, product development, cGMP manufacturing, technology transfer and the management of intellectual property.

PhaseBio Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

PhaseBio Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Similar Private Companies By Industry

Company Name Region
Accupac, Inc. United States
Ceva Animal Health LLC United States
Rapidscan Pharma Solutions, Inc. United States
ProStrakan, Inc. United States
NeuroLogic, Inc. United States

Recent Private Companies Transactions

Private Placement
February 26, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PhaseBio Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at